188 related articles for article (PubMed ID: 14702142)
1. Molecular mechanism of neuropathic pain.
Ueda H; Rashid MH
Drug News Perspect; 2003 Nov; 16(9):605-13. PubMed ID: 14702142
[TBL] [Abstract][Full Text] [Related]
2. What can we learn from failed neuropathic pain trials?
Polydefkis M; Raja SN
Neurology; 2008 Jan; 70(4):250-1. PubMed ID: 18209199
[No Abstract] [Full Text] [Related]
3. Prospects for metabotropic glutamate 1 receptor antagonists in the treatment of neuropathic pain.
Schkeryantz JM; Kingston AE; Johnson MP
J Med Chem; 2007 May; 50(11):2563-8. PubMed ID: 17489573
[No Abstract] [Full Text] [Related]
4. Toward a definition of pharmacoresistant neuropathic pain.
Hansson PT; Attal N; Baron R; Cruccu G
Eur J Pain; 2009 May; 13(5):439-40. PubMed ID: 19324579
[No Abstract] [Full Text] [Related]
5. Kv7 (KCNQ) channel modulators and neuropathic pain.
Munro G; Dalby-Brown W
J Med Chem; 2007 May; 50(11):2576-82. PubMed ID: 17489574
[No Abstract] [Full Text] [Related]
6. N-methyl-D-aspartate antagonists and neuropathic pain: the search for relief.
Childers WE; Baudy RB
J Med Chem; 2007 May; 50(11):2557-62. PubMed ID: 17489572
[No Abstract] [Full Text] [Related]
7. Pharmacotherapy for neuropathic pain.
Jackson KC
Pain Pract; 2006 Mar; 6(1):27-33. PubMed ID: 17309706
[TBL] [Abstract][Full Text] [Related]
8. AMPA glutamate receptors and neuropathic pain.
Morales-Alcelay S; Rubio L; Martinez A
Mini Rev Med Chem; 2003 Nov; 3(7):757-63. PubMed ID: 14529516
[TBL] [Abstract][Full Text] [Related]
9. Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain.
Field MJ; Li Z; Schwarz JB
J Med Chem; 2007 May; 50(11):2569-75. PubMed ID: 17489571
[No Abstract] [Full Text] [Related]
10. Topical analgesics in neuropathic pain.
Sawynok J
Curr Pharm Des; 2005; 11(23):2995-3004. PubMed ID: 16178758
[TBL] [Abstract][Full Text] [Related]
11. Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy.
Bordet T; Buisson B; Michaud M; Abitbol JL; Marchand F; Grist J; Andriambeloson E; Malcangio M; Pruss RM
J Pharmacol Exp Ther; 2008 Aug; 326(2):623-32. PubMed ID: 18492948
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial outcome in neuropathic pain: relationship to study characteristics.
Katz J; Finnerup NB; Dworkin RH
Neurology; 2008 Jan; 70(4):263-72. PubMed ID: 17914067
[TBL] [Abstract][Full Text] [Related]
13. Clinical approach to patients with neuropathic pain.
Stillman M
Cleve Clin J Med; 2006 Aug; 73(8):726-8, 729-30, 733-6 passim. PubMed ID: 16913197
[TBL] [Abstract][Full Text] [Related]
14. Neuropathic pain: molecular complexity underlies continuing unmet medical need.
Kennedy JD
J Med Chem; 2007 May; 50(11):2547-56. PubMed ID: 17489577
[No Abstract] [Full Text] [Related]
15. Current treatment options in neuropathic pain.
Hempenstall K; Rice AS
Curr Opin Investig Drugs; 2002 Mar; 3(3):441-8. PubMed ID: 12054094
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms.
Ueda H
Pharmacol Ther; 2006 Jan; 109(1-2):57-77. PubMed ID: 16023729
[TBL] [Abstract][Full Text] [Related]
17. The ERK/MAPK pathway, as a target for the treatment of neuropathic pain.
Ma W; Quirion R
Expert Opin Ther Targets; 2005 Aug; 9(4):699-713. PubMed ID: 16083338
[TBL] [Abstract][Full Text] [Related]
18. The importance of chemokines in neuropathic pain development and opioid analgesic potency.
Kwiatkowski K; Mika J
Pharmacol Rep; 2018 Aug; 70(4):821-830. PubMed ID: 30122168
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy for neuropathic pain: progress and prospects.
Pullar S; Palmer AM
Drug News Perspect; 2003 Nov; 16(9):622-30. PubMed ID: 14702144
[TBL] [Abstract][Full Text] [Related]
20. Sodium channel blockers.
Kyle DJ; Ilyin VI
J Med Chem; 2007 May; 50(11):2583-8. PubMed ID: 17489575
[No Abstract] [Full Text] [Related]
[Next] [New Search]
